Cencora, Inc. (NYSE:COR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Cencora, Inc. (NYSE:COR) has been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $277.90.

COR has been the topic of a number of recent analyst reports. Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Barclays boosted their target price on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Wells Fargo & Company increased their price target on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their price objective on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 73,187 shares of company stock worth $17,790,912. Company insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Large investors have recently added to or reduced their stakes in the stock. JFS Wealth Advisors LLC boosted its position in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Cencora in the 4th quarter worth approximately $30,000. Concord Wealth Partners purchased a new position in shares of Cencora in the third quarter worth approximately $30,000. Kentucky Trust Co purchased a new position in shares of Cencora in the fourth quarter worth approximately $33,000. Finally, Householder Group Estate & Retirement Specialist LLC grew its position in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 1.3 %

Shares of COR opened at $243.55 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. Cencora has a 12 month low of $214.77 and a 12 month high of $262.26. The firm’s 50 day moving average is $238.70 and its 200-day moving average is $237.21. The stock has a market capitalization of $47.07 billion, a PE ratio of 34.64, a P/E/G ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities research analysts forecast that Cencora will post 15.36 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.90%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.